Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELAD in Alcohol-Induced Liver Decompensation
NCT01471028Phase 3Completed
- Sponsor
- Vital Therapies, Inc.
- Start
- Feb 2013
- Primary completion
- Jan 2015
- Modality
- Cell Therapies, Device-based Delivery
- Countries
- 4
01
Overview
A Phase 3 trial of ELAD in alcoholic liver disease (ALD), sponsored by Vital Therapies, Inc.. Started Feb 2013; status: completed.
02
Drugs
ELAD
03
Conditions
alcoholic liver disease (ALD)
Beyond the preview
Go deeper on NCT01471028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01471028.